You searched for
Category:
#CareBeyondTreatment
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
17/05/2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
08/01/2024
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa Date: 19/12/2023
19/12/2023
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
18/12/2023
Chiesi Group Partnership Day 2023
16/11/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
10/05/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07/03/2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24/02/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
24/02/2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22/02/2023
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18/10/2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
07/04/2022